Home Online Features U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)
U.S. FDA approves Celltrion’s STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)
Hand-out
Press Releases
December 18, 2024

U.S. FDA approves Celltrion’s STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)

By Celltrion

STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn's disease (CD) and ulcerative colitis

bradford

The Bradford Era

email
Local & Social